ソリューション 4 De Novo 小型船舶 IDE トライアル
小さな血管に新規冠状動脈病変を有する被験者の治療における SELUTION SLR™ 014 PTCA 薬剤溶出バルーンの安全性と有効性を評価するための前向き無作為化単盲検多施設研究
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA.
The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a parallel pharmacokinetic (pK) substudy, at up to 80 sites in the US, Canada, Brazil, Japan and Europe. A minimum of 50% of the subjects will be enrolled in the US.
調査の概要
状態
条件
詳細な説明
Prospective, randomized controlled, single-blind, multicenter, clinical trial
The study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a parallel pharmacokinetic (pK) substudy, at up to 80 sites in the US, Canada, Brazil, Japan and Europe. A minimum of 50% of the subjects will be enrolled in the US.
Subjects who present with chronic coronary syndrome (CCS), unstable angina or stabilized non-ST elevation myocardial infarction (NSTEMI) with an indication for percutaneous coronary intervention (PCI) with planned intervention for de novo lesions in small coronary vessels (RVD 2.00 mm to 2.75 mm) and meeting all eligibility criteria will be randomized 1:1 to treatment of the identified target lesion with either the SELUTION SLR 014 PTCA DEB or contemporary DES.
Randomized Cohort:
- Intervention (DEB Strategy): Subjects randomized to the SELUTION SLR 014 PTCA DEB arm will receive lesion preparation according to the 3rd drug coated balloon (DCB) consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, intravascular lithotripsy, laser, rotational or orbital atherectomy, cutting or scoring balloon at the discretion of the operator as needed to reduce diameter stenosis to ≤ 30%). Subjects with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis > 30%) will receive a DES instead of the SELUTION DEB but remain in the SELUTION DEB group (intention to treat analysis). The DEB should not be used after DES implant.
- Control (DES): Subjects randomized to the DES arm will receive treatment using any FDA approved "limus-based" DES, as per standard institutional practice.
Angiographic Substudy:
The angiographic substudy is a parallel registry consisting of up to 30 additional consecutive subjects meeting all eligibility criteria treated with the SELUTION DEB recruited at select study sites. These subjects will undergo angiography at 12 months post-procedure. Clinical follow-up will not extend beyond 12 months in this cohort.
Pharmacokinetic (pK) Substudy:
The pKsubstudy is a parallel registry consisting of up to 20 additional consecutive subjects meeting all eligibility criteria treated with the SELUTION DEB recruited at select study sites. This study will be conducted under an approved substudy protocol and will include blood draws at regular intervals to characterize the pK plasma profile of sirolimus.
Primary Endpoint:
Target lesion failure (TLF), defined as the composite of cardiac death, target-vessel myocardial infarction (MI) or clinically-driven target lesion revascularization (TLR) at 12 months. MI includes spontaneous (Type 1) MI using the 4th Universal Definition of Myocardial Infarction (UDMI) and peri-procedural MI using the Society for Cardiac Angiography and Intervention (SCAI) definition.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Arkansas
-
Jonesboro、Arkansas、アメリカ、72401
- St. Bernards
-
-
California
-
Chula Vista、California、アメリカ、91911
- CISD Sharp Chula Vista
-
Los Angeles、California、アメリカ、90048
- Cedars Sinai
-
Thousand Oaks、California、アメリカ、91360
- HCA Los Robles
-
Torrance、California、アメリカ、90502
- Harbor UCLA
-
-
Colorado
-
Golden、Colorado、アメリカ、80401
- Colorado Heart and Vascular
-
Thornton、Colorado、アメリカ、80023
- ClinRe
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06520
- Yale New Haven Hospital
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- MedStar Washington Hospital Center
-
-
Florida
-
Bradenton、Florida、アメリカ、34208
- Manatee Memorial
-
Clearwater、Florida、アメリカ、34695
- Mease Countryside Hospital
-
Jacksonville、Florida、アメリカ、32209
- University of Florida, Jacksonville
-
Largo、Florida、アメリカ、33770
- HCA Largo
-
Orlando、Florida、アメリカ、32803
- AdventHealth Orlando
-
St. Petersburg、Florida、アメリカ、33709
- HCA Northside
-
Trinity、Florida、アメリカ、34655
- HCA Trinity
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30309
- Piedmont Heart Institute
-
Atlanta、Georgia、アメリカ、30033
- Atlanta VA
-
Atlanta、Georgia、アメリカ、30322
- Emory
-
Dalton、Georgia、アメリカ、30720
- Hamilton Medical Center
-
Thomasville、Georgia、アメリカ、31792
- Archbold Memorial Hospital
-
-
Hawaii
-
‘Aiea、Hawaii、アメリカ、96701
- Pali Momi Medical Center
-
-
Illinois
-
Downers Grove、Illinois、アメリカ、60515
- Advocate Good Samaritan Hospital
-
Oak Lawn、Illinois、アメリカ、60453
- Advocate Christ Medical Center
-
Urbana、Illinois、アメリカ、61801
- Carle Foundation Hospital
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa Medical Center
-
-
Kansas
-
Wichita、Kansas、アメリカ、67226
- Cardiovascular Research Institute of Kansas
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40503
- Baptist Health Lexington
-
-
Louisiana
-
Houma、Louisiana、アメリカ、70360
- Cardiovascular Institute of the South
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21201
- University of Maryland
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02115
- Brigham & Women's
-
Boston、Massachusetts、アメリカ、02114
- Mass General
-
Boston、Massachusetts、アメリカ、02114
- Beth Israel Deaconess
-
Springfield、Massachusetts、アメリカ、01199
- Baystate Medical Center
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55417
- Minneapolis VA Medical Center
-
Minneapolis、Minnesota、アメリカ、55407
- Minneapolis Heart Institute
-
-
Mississippi
-
Tupelo、Mississippi、アメリカ、38801
- North Mississippi Medical Center
-
-
Missouri
-
Overland Park、Missouri、アメリカ、66211
- HCA Overland Park
-
St Louis、Missouri、アメリカ、63136
- St. Louis Heart and Vascular
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68198
- University of Nebraska
-
-
New Jersey
-
Englewood、New Jersey、アメリカ、07631
- Englewood Health
-
-
New York
-
New York、New York、アメリカ、10029
- Icahn School of Medicine at Mount Sinai
-
New York、New York、アメリカ、10075
- Northwell Health Lenox Hill
-
Stony Brook、New York、アメリカ、11794
- Stony Brook University Hospital
-
-
North Carolina
-
Raleigh、North Carolina、アメリカ、27607
- NC Heart and Vascular
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45219
- The Lindner Research Center at Christ
-
Cleveland、Ohio、アメリカ、44120
- UH Cleveland
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73120
- Oklahoma Heart
-
-
Pennsylvania
-
Hershey、Pennsylvania、アメリカ、17033
- Penn State Health Hershey & Berks
-
Mechanicsburg、Pennsylvania、アメリカ、17050
- UPMC Pinnacle
-
York、Pennsylvania、アメリカ、17403
- WellSpan York Hospital
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02903
- Lifespan Rhode Island & Miriam
-
-
Tennessee
-
Chattanooga、Tennessee、アメリカ、37404
- CHI Memorial
-
Chattanooga、Tennessee、アメリカ、37404
- University of Nebraska
-
Nashville、Tennessee、アメリカ、37203
- HCA Centennial
-
-
Texas
-
Abilene、Texas、アメリカ、79601
- Hendrick Health
-
Dallas、Texas、アメリカ、75231
- Texas Health
-
Dallas、Texas、アメリカ、75246
- Baylor Scott and White - Dallas
-
Fort Worth、Texas、アメリカ、76104
- Medical City of Fort Worth
-
Plano、Texas、アメリカ、75093
- Baylor Scott and White Plano
-
Temple、Texas、アメリカ、76508
- Baylor Scott and White - Temple
-
-
Utah
-
Murray、Utah、アメリカ、84107
- Intermountain Health - Salt Lake City
-
-
Virginia
-
Richmond、Virginia、アメリカ、23225
- HCA Chippenham
-
-
West Virginia
-
Charleston、West Virginia、アメリカ、25304
- CAMC
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53215
- Advocate Aurora St. Luke's
-
-
-
-
-
Bad Krozingen、ドイツ、79189
- Universitäts-Herzzentrum Freiburg
-
Berlin、ドイツ、12683
- UKB Berlin
-
Dresden、ドイツ、01307
- Herzzentrum Dresden
-
-
-
-
-
Genk、ベルギー、3600
- ZOL Genk
-
Hasselt、ベルギー、3500
- Hartcentrum Hasselt Jessa Ziekenhuis
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Clinical Inclusion Criteria
Subjects must meet all of the following clinical criteria to participate in the trial:
- Subject is ≥ 18 years (or the minimum legal age as required by local regulations).
- Female subjects of childbearing potential must have a negative pregnancy test ≤ 7 days before the procedure or are using a contraceptive device or drug.
- Subject presents with chronic coronary syndromes [CCS] (manifest as documented angina or positive functional testing), unstable angina or stabilized non-ST elevation myocardial infarction (NSTEMI) (biomarkers stabilized or down trending) with an indication for PCI and planned intervention.
- Subject can tolerate dual antiplatelet therapy with aspirin, plus either Clopidogrel, Prasugrel, or Ticagrelor. (Note: For subjects requiring oral anticoagulation, aspirin may be omitted based on investigator discretion).
- Subject has life expectancy > 1 year in the opinion of the investigator.
- Subject is willing and able to provide informed consent and comply with study procedures and required follow-up evaluations.
PK Sub- Study Inclusion Criteria:
Subjects must meet all of the main protocol inclusion criteria to participate in the PK sub-study. Subjects must also meet the following additional PK sub-study inclusion criteria:
1. Subject is willing and able to provide informed consent for the PK sub-study and comply with the PK sub-study procedures and required follow-up evaluations.
Imaging Inclusion Criteria
Subject's target lesion(s) must meet all of the following angiographic criteria for the subject to participate in the trial:
- A single, target lesions that meet criteria can be treated in a single vessel. No non-target lesions can be treated within the target vessel in the index procedure. Non-target lesions within the target vessel can be staged for treatment > 30 days from the index procedure.
- Up to two (2) non-target lesions in up to two (2) non-target vessels may be treated, but successful PCI of the non-target lesions must be completed before randomization and treatment of the target lesion.
- Target lesion is ≤ 36 mm in length.
- Target lesion has diameter stenosis > 50% and ≤ 99% with distal flow at least thrombolysis in myocardial infarction (TIMI) 2.
- Target vessel has RVD of ≥ 2.00 mm and ≤ 2.75 mm [by visual assessment].
- Target lesion is within a native coronary artery or major branch.
- A target lesion within a bifurcation is allowed only if a single vessel (either main vessel or side branch) is to be treated.
- The identified target lesion has high probability for successful treatment with approved pre-treatment techniques and DEB alone based on Investigator assessment.
Exclusion Criteria:
- Clinical Exclusion Criteria
Subjects who meet any of the following clinical criteria will be excluded from the trial:
- Subject with known hypersensitivity or allergy to Sirolimus or its analogues.
- Subject presents with NSTEMI and rising biomarkers, or ongoing chest pain or is hemodynamically instable.
- Subject with history of ST-elevation myocardial infarction (STEMI) within 30 days of the index procedure.
- Subject with planned major surgery within 30 days following the index procedure.
- Subject with planned treatment of lesion involving aorto-ostial location.
- Subject with PCI of a non-target vessel within ± 30 days of the index procedure.
- Subject with history (within 6 months prior to index procedure) of New York Heart Association (NYHA) class III or IV heart failure.
- Subject with history of active peptic ulcer or gastrointestinal bleeding within 6 months of the index procedure or other inability to comply with the recommended duration of dual antiplatelet therapy (DAPT).
- Subject is pregnant, breast-feeding or a woman of childbearing potential who plans pregnancy up to 1 year following index procedure.
- Subjects with current documented left ventricular ejection fraction (LVEF) < 30%.
- Subject is considered not able to tolerate at least 30 seconds of coronary occlusion for the target lesion treated.
- Subjects is currently participating in another investigational drug or device study that has not completed primary endpoint follow-up.
- Subject with definite clinically active COVID-19 infection defined as a positive COVID test within 24 hours of index procedure.
- Subject has chronic renal insufficiency (dialysis dependent, or glomerular filtration rate [GFR] ≤ 30 ml/min/1.73 m2 within 30 days of index procedure) or had undergone renal transplantation.
PK Sub-Study Exclusion Criteria:
Subjects must meet none of the main protocol exclusion criteria to participate in the PK sub-study. Subjects will be excluded if any of the following additional PK sub-study exclusion criteria are met:
-
Any limus family (Zotarolimus, Everolimus, Sirolimus etc.) eluting device has been placed/used in any part of the body within 3 months prior to the index procedure including non-target lesion(s) treated during the index procedure.
-
Planned intervention with any limus family (Zotarolimus, Everolimus, Sirolimus etc.) eluting device anywhere in the body within 6 months after the index procedure. Note: staged procedures >30 days after index procedure (Exclusion #6 of the main protocol) are permitted only in the main protocol, and are not permitted in this PK sub-study.
-
The subject is taking or has taken within the last 3 months any limus family medication(s) for any reason.
-
Subject is concurrently enrolled in the main protocol angiographic registry.
-
Subjects who are taking strong CYP3A4 Inhibitors within 14 days before the index procedure or plan to take the strong inhibitors during the study period. Strong inhibitors include: cobicistat; ritonavir; indinavir and ritonavir; itraconazole; ketoconazole; lopinavir and ritonavir; paritaprevir and ritonavir and ombitasvir (and/or dasabuvir); posaconazole; saquinavir and ritonavir; tipranavir and ritonavir; elvitegravir and ritonavir; telithromycin; voriconazole; ceritinib; clarithromycin; idealalisib; nefazodone; nelfinavir.
-
Subjects who are taking strong CYP3A4 Inducers within 14 days before the index procedure or plan to take the strong inducers during the study period. Strong inducers include apalutamide; carbamazepine; enzalutamide; ivosidenib; lumacaftor and ivacaftor; mitotane; phenytoin; rifampin; St. John's wort.
- Angiographic Exclusion Criteria
Subject whose target lesion(s) meet any of the following angiographic criteria will be excluded from the trial:
- Target lesion is totally occluded or has evidence of thrombus.
- Target lesion is located in the left main or any arterial or venous graft.
- Target lesion is in a side branch that is "jailed" by a main vessel stent.
- In stent restenosis
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:SELUTION SLR 014 PTCA DEB
SELUTION Sustained Limus Release (SLR) 014 Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon (DEB) The SELUTION SLR 014 PTCA DEB is a minimally invasive, single use and sterile Sirolimus coated PTCA balloon catheter. The SELUTION SLR 014 PTCA DEB is available with balloon diameters from 2.0 to 3.0 mm and lengths of 15 to 40 mm for the purpose of the De Novo IDE trial |
After target lesion pre-dilatation and preparation , a SELUTION SLR 014 PTCA DEB study device should be selected with nominal diameter equal to the RVD of the target lesion (1:1 ratio) and length that allows approximately 2.00 mm longer than the proximal and distal edges of the target lesion (defined as the proximal and distal extent of predilation). If IVUS is performed to assess RVD, and DEB upsizing is deemed clinically necessary for optimal results, a maximum nominal DEB diameter of 3.0 mm is permitted. The SELUTION SLR 014 PTCA DEB should then be delivered, positioned in and deployed per instructions per use. The balloon should be inflated for 60 seconds provided that the patient can tolerate this duration. The minimum inflation time is 30 seconds. |
|
アクティブコンパレータ:Control Treatment
any FDA approved "limus-based" Drug Eluting Stent, as per standard institutional practice |
For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices. The DES should be sized per IFU with respect to the vessel RVD. The use of IVUS or OCT is encouraged to guide optimal stent placement and assess final results. After DES deployment, additional balloon inflations should be performed as needed to obtain < 30% residual diameter stenosis and resolve proximal or distal edge dissections greater than or equal to NHLBI grade B. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Target lesion failure (TLF)
時間枠:12 months
|
Target lesion failure (TLF) is defined as the composite of cardiac death, target-vessel myocardial infarction (MI) or clinically-driven target lesion revascularization (TLR) at 12 months. MI includes spontaneous (Type 1) MI using the 4th Universal Definition of Myocardial Infarction (UDMI) and peri-procedural MI using the Society for Cardiac Angiography and Intervention (SCAI) definition. |
12 months
|
|
PK Sub-study Primary Endpoint 1
時間枠:6 months
|
PK parameters of C(max) |
6 months
|
|
PK Sub-study Primary Endpoint 2
時間枠:6 months
|
PK parameters of T(max) |
6 months
|
|
PK Sub-study Primary Endpoint 3
時間枠:6 months
|
PK parameters of AUC(last) |
6 months
|
|
PK Sub-study Primary Endpoint 4
時間枠:6 months
|
PK parameters of MRT(last) |
6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Secondary Endpoint 1
時間枠:12 months
|
Composite of all-cause mortality, target vessel MI or clinically driven target lesion revascularization |
12 months
|
|
Secondary Endpoint 2
時間枠:Up to 7 days
|
Lesion success, defined as attainment of < 30% residual stenosis of target lesion using any percutaneous method |
Up to 7 days
|
|
Secondary Endpoint 3
時間枠:Up to 7 days
|
Procedure success, defined as attainment of < 30% residual stenosis of the target lesion using the assigned study device only without the occurrence of in-hospital major adverse cardiac events (MACE), composite of all-cause death, MI or any clinically-driven TLR. |
Up to 7 days
|
|
Secondary Endpoint 4
時間枠:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
Composite safety endpoint, defined as the patient-oriented composite of any death, any MI (spontaneous or peri-procedural), or any repeat revascularization. |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 5
時間枠:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
All-Cause Mortality |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 6
時間枠:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
Cardiovascular Mortality |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 7
時間枠:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
MI (spontaneous MI using the 4th UDMI, peri-procedural MI using SCAI and Academic Research Consortium [ARC]-2 definitions) |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 8
時間枠:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
Clinically-driven TLR |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 9
時間枠:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
all TLR |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 10
時間枠:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
Clinically-driven Target Vessel Revascularization (TVR) |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 11
時間枠:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
all TVR |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 12
時間枠:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
Non-target lesion revascularization |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 13
時間枠:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
TLF |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 14
時間枠:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
Target vessel failure (TVF), defined as a composite of: cardiac death, target vessel MI (spontaneous or peri-procedural) and any clinically-driven TVR |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 15
時間枠:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
Stent or target lesion segment thrombosis (definite or probable) according to the ARC criteria for acute, subacute, late, very late and cumulative stent thrombosis |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 16
時間枠:12 months
|
Bleeding Academic Research Consortium (BARC) class 2-5 |
12 months
|
|
Secondary Endpoint 17
時間枠:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
Net adverse clinical events, defined as death, MI (spontaneous or peri-procedural), TVR, stent/target lesion segment thrombosis or bleeding (BARC types 2-5, assessed to 12 months) |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
PK Sub-Study Secondary Endpoint 1
時間枠:6 months
|
If calculations are valid, additional PK parameter of AUC(inf). |
6 months
|
|
PK Sub-Study Secondary Endpoint 2
時間枠:6 months
|
If calculations are valid, additional PK parameter of Cl. |
6 months
|
|
PK Sub-Study Secondary Endpoint 3
時間枠:6 months
|
If calculations are valid, additional PK parameter of Vz. |
6 months
|
|
PK Sub-Study Secondary Endpoint 4
時間枠:6 months
|
If calculations are valid, additional PK parameter of Vss. |
6 months
|
|
PK Sub-Study Secondary Endpoint 5
時間枠:6 months
|
If calculations are valid, additional PK parameter of half-life. |
6 months
|
|
PK Sub-Study Secondary Endpoint 6
時間枠:6 months
|
Dose normalized C(max) will be considered if appropriate. |
6 months
|
|
PK Sub-Study Secondary Endpoint 7
時間枠:6 months
|
Dose normalized AUC will be considered if appropriate. |
6 months
|
|
PK Sub-Study Secondary Endpoint 8
時間枠:6 months
|
Device success, defined as attainment of ≤ 30% residual stenosis of the target lesion using the assigned device only |
6 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Ron Waksman, MD、Medstar Health Research Institute
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- SEL-003-2021
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。